The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis

Figures & data

Figure 1. Schematic of literature retrieval.

Table 1. Characteristics of included studies.

Author year	Study design	Male %	Sample size	Region	Diagnosis of MASLD	Follow-up(year)	Quality score
Alexander M 2019(a)	Prospective cohort study	57.2	1542672	Italy	ICD	5.5	8 scores
Alexander M 2019(b)	Prospective cohort study	48.5	2225925	Netherlands	Others	2.1	8 scores
Alexander M 2019(c)	Prospective cohort study	52.5	5488397	Spain	ICD	3.7	8 scores
Alexander M 2019(d)	Prospective cohort study	51.1	12695046	UK	Others	3.5	8 scores
Labenz C 2019	Prospective cohort study	50.2	44096	Germany	ICD	1	7 scores
Ghoneim S 2020	Retrospective cohort study	45	55099280	United States	Others	1	8 scores
Sinn DH 2019	Retrospective cohort study	51.2	111492	South Korea	Ultrasonography	6.15	9 scores
Dai L 2021	Prospective cohort study	24.6	79905	China	Ultrasonography	10.3	8 scores
Chung GE 2021	Prospective cohort study	56.45	5324410	Korean	Others	8.4	8 scores
Allen AM 2021	Prospective cohort study	47.56	19078	Minnesota	ICD	7	7 scores

ICD: international classification of diseases; MASLD: metabolic dysfunction-associated steatotic liver disease.

Figure 2. Forest plot of the association between MASLD and MI risk.

Figure 3. Forest plot of the subgroup analysis of study region.

Figure 4. Forest plot of the subgroup analysis of MASLD diagnosis.

Figure 5. Forest plot of the subgroup analysis of the quality score.

Figure 6. Forest plot of the subgroup analysis of the study design.

Figure 7. Forest plot of the subgroup analysis of the follow-up duration.

Figure 8. Sensitivity analysis of the association of MASLD with MI risk.

Figure 9. Funnel plot of the literature publication bias on the association between MASLD and MI risk.

Data availability statement

Data availability is not applicable to this article as no new data were created or analyzed in this study.